Brokerage firm in hot water again after regulator dolls out fine after underwriting a now-troubled landscaping construction company in 2018

After being penalized for its role in Kangmei Pharmaceutical case, GF creates a new investment banking business committee

Implicated in Kangmei Pharmaceutical’s financial fraud, GF Securities has been suspended from sponsoring listings

Brokerage ditched by longtime partner as joint lead underwriter for 15 billion yuan private placement

Brokerage house is banned from sponsoring listings for six months and from bond underwriting for a year as CSRC singles out 14 individuals for punishment

As a result of latest sanctions, Chinese tech giant may have to sharply scale back or even shutter its fast-growing HiSilicon unit, analysts say

Scandal-plagued supplier of traditional medicines in credit crunch says it raised less than half the funds and will continue scraping up cash to repay debt

Brokerage’s compliance department is not independent enough, has too few experienced staff, regulator says

Watchdog limits scale of derivatives business, addition of new types of business for six months

Central bank raises five major companies’ quotas for short-term commercial paper to boost liquidity

Head of one of GF Securities’ Hong Kong subsidiaries resigns after last year’s $139 million loss dragged down brokerage’s bottom line

Unit records $139 million of red ink, drawing rebuke from Guangdong regulators and threatening Citigroup loan